MedTrace Logo

Phase 1 Study to Evaluate ASN002 Absorption, Metabolism, and Excretion of [14C] Following a Single Oral Dose in Healthy Male Subjects

NCT03641573 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2020-05-28

No results posted yet for this study

Summary

Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of \[14C\] ASN002 Following a Single Oral Dose in Healthy Male Subjects

Conditions

  • Healthy Volunteer

Interventions

DRUG

[14C] ASN002

\[14C\] ASN002

Sponsors & Collaborators

  • Asana BioSciences

    lead INDUSTRY

Principal Investigators

  • Niranjan Rao, PhD · Asana BioSciences

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-11
Primary Completion
2018-10-21
Completion
2018-10-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03641573 on ClinicalTrials.gov